W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells
Beata Herberger,Walter Berger,Harald Puhalla,Katharina Schmid,Sabine Novak,Anita Brandstetter,Christine Pirker,Thomas Gruenberger,Martin Filipits +8 more
TL;DR: Results suggest that combined targeted therapy with EGFR and mTOR inhibitors may potentially benefit patients with BTAs and should be further evaluated in clinical trials.
Journal ArticleDOI
Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy
Nastasia Wilfinger,Shane Austin,Barbara Scheiber-Mojdehkar,Walter Berger,Siegfried Reipert,Monika Praschberger,Jakob Paur,Robert Trondl,Bernhard K. Keppler,Christoph C. Zielinski,Karin Nowikovsky +10 more
TL;DR: Targeting BNIP3L in wild-type p53 colon cancer cells is a novel anticancer strategy activating iron depletion signaling and the mitophagy-related cell death pathway.
Journal ArticleDOI
EVI1 promotes tumor growth via transcriptional repression of MS4A3
Gerwin Heller,Anna Rommer,Katarina Steinleitner,Julia Etzler,Hubert Hackl,Petra Heffeter,Erwin Tomasich,Martin Filipits,Birgit Steinmetz,Thais Topakian,Simone Klingenbrunner,Barbara Ziegler,Andreas Spittler,Sabine Zöchbauer-Müller,Walter Berger,Rotraud Wieser +15 more
TL;DR: MS4A3 is revealed as a novel direct target of EVI1 in human myeloid cells, and its repression plays a role in EVI 1 mediated tumor aggressiveness.
Journal ArticleDOI
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Zsuzsanna Bago-Horvath,Wolfgang Sieghart,Michael Grusch,Andreas Lackner,Hubert Hayden,Christine Pirker,Oxana Komina,Józefa Węsierska-Gądek,Andrea Haitel,Martin Filipits,Walter Berger,Katharina Schmid +11 more
TL;DR: This study indicates that EGFR and mTOR are clinically important targets in bronchial neuroendocrine tumors, and further in vivo and clinical exploration of combined inhibition is warranted.
Journal ArticleDOI
Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways.
Eva Bernhart,Sabine Damm,Petra Heffeter,Andrea Wintersperger,Martin Asslaber,Saša Frank,Astrid Hammer,Heimo Strohmaier,Trevor DeVaney,Manuel Mrfka,Hans G. Eder,Christian Windpassinger,Christopher R. Ireson,Paul S. Mischel,Walter Berger,Wolfgang Sattler +15 more
TL;DR: RNA-interference and pharmacological inhibition of PRKD2 profoundly inhibited proliferation of p53wt (U87MG, A172, and primary GBM2), and p53mut (GM133, T98G, U251, andPrimary Gli25) glioma cells.